Dolutegravir Pediatric Liquid Formulation Study

NCT03921723 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Dolutegravir dispersible tablet
DRUG: Dolutegravir oral suspension
DRUG: Dolutegravir oral solution

Sponsor

ViiV Healthcare